Injected Bupivacaine intraperitoneally — Competitive Intelligence Brief

Injected Bupivacaine intraperitoneally (Injected Bupivacaine intraperitoneally) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management / Anesthesia.

phase 3 Local anesthetic Voltage-gated sodium channels Pain management / Anesthesia Small molecule

Target snapshot

Injected Bupivacaine intraperitoneally (Injected Bupivacaine intraperitoneally) — Imperial College London. Bupivacaine injected intraperitoneally blocks sodium channels in nerve fibers within the peritoneal cavity, providing local anesthesia and analgesia to abdominal tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Injected Bupivacaine intraperitoneally TARGET	Injected Bupivacaine intraperitoneally	Imperial College London	phase 3	Local anesthetic	Voltage-gated sodium channels
carbamazepine ER (Equetro)	carbamazepine ER (Equetro)	Massachusetts General Hospital	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class